No Yes Ok

Archive

« Older Entries Newer Entries »

LSP leads EUR 24 mln Series A financing of eTheRNA to develop its TriMix mRNA-based immunotherapy Monday, March 14th, 2016
Amsterdam, the Netherlands – 14 March 2016 – eTheRNA immunotherapies, a spin-off from the Brussels University ‘Vrije Universiteit Brussel’ (VUB), secured EUR 24 million in a Series A investment round with vent [...]
TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients Tuesday, March 8th, 2016
A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 52 in the treatment of complex perianal fistulas in Crohn's disease patients with inadequate response t [...]
Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge Tuesday, February 23rd, 2016
- Data and CE-IVD launch expected in Q2, 2016 - Company also prepares launch of 2nd generation ITI Application Cartridge and novel product for intra-abdominal infections   Amsterdam, the Netherlands [...]
First full hospital roll-out of MedEye in the Netherlands Wednesday, February 17th, 2016
LSP’s portfolio company Mint Solutions provides for the first time an entire hospital with its medication safety system. At Deventer Hospital, which has tested the solution since August last year, the system will so [...]
Digital health and medtech come alive Tuesday, February 16th, 2016
Healthcare investing comes of age The stage is all set for another good year in healthcare. Medical technology (medtech) and digital health are gaining traction with investors, insurers and governments (payers), [...]
Atlas Genetics Gains CE Approval for First Product Monday, February 8th, 2016
Approval of Chlamydia test for marketing and sale in Europe   Bath, UK, February 08, 2016. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnos [...]
LSP’s Nexstim and its impact in brain surgery Thursday, February 4th, 2016
For more info click here [...]
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes Thursday, February 4th, 2016
The Phase 2 trial is an important step in the dual product development of ZP4207: both as a rescue pen to treat severe hypoglycemia and as an essential component in an artificial pancreas device for better diabe [...]
Curetis Expands Commercial Team Tuesday, February 2nd, 2016
- Company hires Willem Haagmans as Head of Sales EMEA -   Amsterdam, the Netherlands and Holzgerlingen, Germany, February 3, 2016 -- Curetis N.V. (the "Company" and, together with Curetis AG, "Curetis"), a de [...]
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma Monday, January 25th, 2016
Heidelberg, Germany, January 25, 2016 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today t [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
Follow us

No Yes Ok

Archive

« Older Entries Newer Entries »

LSP leads EUR 24 mln Series A financing of eTheRNA to develop its TriMix mRNA-based immunotherapy Monday, March 14th, 2016
Amsterdam, the Netherlands – 14 March 2016 – eTheRNA immunotherapies, a spin-off from the Brussels University ‘Vrije Universiteit Brussel’ (VUB), secured EUR 24 million in a Series A investment round with vent [...]
TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn's disease patients Tuesday, March 8th, 2016
A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 52 in the treatment of complex perianal fistulas in Crohn's disease patients with inadequate response t [...]
Curetis Starts Final Validation Study for New Unyvero Blood Culture Application Cartridge Tuesday, February 23rd, 2016
- Data and CE-IVD launch expected in Q2, 2016 - Company also prepares launch of 2nd generation ITI Application Cartridge and novel product for intra-abdominal infections   Amsterdam, the Netherlands [...]
First full hospital roll-out of MedEye in the Netherlands Wednesday, February 17th, 2016
LSP’s portfolio company Mint Solutions provides for the first time an entire hospital with its medication safety system. At Deventer Hospital, which has tested the solution since August last year, the system will so [...]
Digital health and medtech come alive Tuesday, February 16th, 2016
Healthcare investing comes of age The stage is all set for another good year in healthcare. Medical technology (medtech) and digital health are gaining traction with investors, insurers and governments (payers), [...]
Atlas Genetics Gains CE Approval for First Product Monday, February 8th, 2016
Approval of Chlamydia test for marketing and sale in Europe   Bath, UK, February 08, 2016. Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnos [...]
LSP’s Nexstim and its impact in brain surgery Thursday, February 4th, 2016
For more info click here [...]
Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes Thursday, February 4th, 2016
The Phase 2 trial is an important step in the dual product development of ZP4207: both as a rescue pen to treat severe hypoglycemia and as an essential component in an artificial pancreas device for better diabe [...]
Curetis Expands Commercial Team Tuesday, February 2nd, 2016
- Company hires Willem Haagmans as Head of Sales EMEA -   Amsterdam, the Netherlands and Holzgerlingen, Germany, February 3, 2016 -- Curetis N.V. (the "Company" and, together with Curetis AG, "Curetis"), a de [...]
Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Hodgkin Lymphoma Monday, January 25th, 2016
Heidelberg, Germany, January 25, 2016 -­ Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today t [...]

« Older Entries Newer Entries »

2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to archive overview
X

MONTHLY REPORTS

Here you can subscribe for the monthly report of the LSP Life Sciences Fund